TGA issues product defect correction


Pharmacists are advised that Janssen is undertaking a product defect correction for one batch of Jurnista (hydromorphone hydrochloride) prolonged-release blister packs Janssen, following consultation with the TGA, is undertaking a product defect correction for one batch of Jurnista (hydromorphone hydrochloride) prolonged-release blister packs (8 mg, 14 tablets) due to potential damage to the tablets. A misalignment issue with

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Don't listen to only pharmacists on 7CPA
Next Pollies back pharmacists in harm minimisation